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Abstract 
Context: There are few short-term mouse models of chronic obstructive 
pulmonary disease (COPD) mimicking the human disease. In addition, p38 is 
recently recognized as a target for the treatment of COPD. However, the precise 
mechanism how p38 contributes to the pathogenesis of COPD is still unknown. 
Objective: We attempted to create a new mouse model for COPD by intratracheal 
administration of a mixture of lipopolysaccharide (LPS) and cigarette smoke 
solution (CSS), and investigated the importance of the p38 mitogen-activated 
protein kinase (p38) pathway in the pathogenesis of COPD. 
Methods: Mice were administered LPS+CSS once a day on days 0-4 and 7-11. 
Thereafter, CSS alone was administered to mice once a day on days 14-18. On day 
28, histopathological changes of the lung were evaluated, and bronchoalveolar 
lavage fluid (BALF) was subjected to western blot array for cytokines. Transgenic 
(TG) mice expressing a constitutive-active form of MKK6, a p38-specific activator 
in the lung, were subjected to our experimental protocol of COPD model. 
Results: LPS+CSS administration induced enlargement of alveolar air spaces and 
destruction of lung parenchyma. BALF analyses of the LPS+CSS group revealed 
an increase in expression levels of several cytokines involved in the pathogenesis 
of human COPD. These results suggest that our experimental protocol can induce 
COPD in mice. Likewise, histopathological findings of the lung and induction of 
cytokines in BALF from MKK6 c.a.-TG mice were more marked than those in WT 
mice. 
Conclusion: In a new experimental COPD mouse model, p38 accelerates the 
development of emphysema. 
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is a slowly progressive disease 
characterized by airflow limitation that is not fully reversible. Cigarette smoking 
has been generally accepted as the most important risk factor for the development 
of COPD. However, only 15-20% of heavy smokers develop clinically significant 
airflow obstruction (1), which suggests a genetic susceptibility to the effects of 
cigarette smoking. Several pathophysiologic processes interact on a complex 
background of genetic and environmental factors, but the detailed course of the 
disease is not fully elucidated. 
Based on prevalence surveys, it is estimated that 10% of adults aged 40 years 
and older have COPD (2). COPD was ranked sixth in the causes of death in 1990, 
and will become the third leading cause of death by 2030 (3). These data suggest 
that COPD will become a major health problem in the next few decades. 
The mainstay of current therapy for COPD is inhaled bronchodilators. There is 
a pressing need to develop new treatments for COPD, because most studies have 
indicated that the existing medications for COPD do not modify the long-term 
decline in lung function (4). The use of appropriate experimental COPD animal 
models is indispensable for the development of new therapy and for better 
understanding of the disease. 
A variety of different approaches have been used to attempt to model COPD in 
animals (5). Administration of proteinases, chemicals and particulates, cigarette 
smoke exposure and genetic manipulation have successfully produced features 
characteristic of human COPD. Although the cause of the disease tempts us to 
consider a smoke exposure model as the most reasonable model, it takes more 
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than 3 months to induce emphysema (6). In order to shorten the period, Mizutani 
et al. employed intratracheal administration of cigarette smoke solution (CSS) 
and lipopolysaccharide (LPS) and created a guinea pig COPD model that requires 
only 19 days (7), indicating the possibility that this protocol could enable us to 
investigate the pathogenesis of COPD more easily. 
The p38 mitogen-activated protein kinase (p38) signaling pathway is activated 
by a variety of extracellular stimuli including cellular stress, inflammatory 
cytokines and cell surface receptors, and plays a role in a wide range of cellular 
responses, such as proliferation, differentiation and apoptosis (8). In particular, 
the notion that p38 functions as a central player in inflammatory diseases has 
been supported by various reports including our studies (9, 10). Also in lung 
inflammatory diseases, p38 is recognized as a potential therapeutic target. Indeed, 
pirfenidone, a p38γ inhibitor, is used for the treatment of patients with idiopathic 
pulmonary fibrosis (11). Likewise, it has been reported that p38 is activated in the 
alveolar macrophages of COPD patients compared to healthy controls (12), 
suggesting that p38 might be a plausible target for the treatment of COPD. 
Here, we first investigated whether the protocol for the guinea pig COPD model 
could be applied to mice. Then, we established a new experimental COPD mouse 
model. We next investigated the participation of p38 in the pathogenesis of COPD, 
using MKK6 c.a.-TG mice in which the MKK6 constitutive-active gene is 
introduced under control of the human surfactant protein C (SP-C) gene promoter. 
 
Materials and Methods 
 
Animals 
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Male C57BL/6J mice at 10 weeks of age were purchased from Clea Japan 
(Tokyo, Japan). To generate MKK6 constitutive-active (c.a., dual mutations in 
wild human MKK6: Ser207 to Asp; Tyr211 to Asp) TG mice, the linear 5.3 k-bp 
hSPC-3HA-tag-hMKK6 c.a. NarI/NotI-fragment (Supplemental Fig. 1A) was 
microinjected in eggs from C57BL/6J mice, which were subsequently transplanted 
into the uteli of pseudopregnant female ICR mice. For construction of the 
transgene, the 3.7SPC/SV40 vector was provided by Dr. Jeffrey A. Whitsett, 
Children's Hospital Medical Center, Division of Pulmonary Biology, Cincinnati, 
Ohio. Although we obtained five lines of TG F1 mice, the four TG lines with high 
expression level of transgene-derived MKK6 c.a. showed low fertility rate. As a 
result, only one line of MKK6 c.a.-TG mice could be maintained. In the lung of 
MKK6 c.a.-TG mice, the expression of HA-tag+/41-KDa protein corresponding to 
the predicted size of 3HA-tag-MKK6 c.a. was confirmed by western blot (WB) 
analysis, and immunofluorescence study revealed the colocalization of 
HA-tag-like immunoreactivity (LI) and proSP-C-LI  (Supplemental Fig. 1B&C). 
These indicate that the transgene-derived MKK6 c.a. is successfully expressed at 
least in type II alveolar epithelial cells. Male heterozygous TG mice and WT 
littermates at 10 weeks of age were used for experiments (Supplemental Fig. 1D). 
Animals were housed in standard laboratory cages and allowed food and water 
throughout the experiments. The studies were performed according to a protocol 
approved by the Committee of Animal Welfare of Chiba University. 
 
Reagents 
LPS (Escherichia coli, serotype) was purchased from Sigma-Aldrich Co. 
Cigarette smoke solution (CSS) was purchased from Sugi Institute of Biological 
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Science Co. (Yamanashi, Japan). 
 
Experimental protocol of intratracheal administration 
The two administration protocols employed in this study are shown in Fig. 1A 
(Protocol A) and Fig. 2A (Protocol B). In Protocol A, CSS (diluted 4 fold with PBS, 
50 µl/body) was intratracheally administered to mice once a day on days 0-3, 5-8, 
10-13 and 15-18, and LPS (200 µg/ml, 50 µl/body) was administered once a day on 
days 4, 9 and 14. Mice were sacrificed on day 19. In Protocol B, a mixture of CSS 
(diluted 4 fold with PBS, 25 µl/body) and LPS (25 µg/ml, 25 µl/body) was 
intratracheally administered to mice once a day on days 0-4 and 7-11, and then 
CSS was administered to mice once a day on days 14-18. Mice were sacrificed on 
day 28 after a 10-day period of no treatment. As a negative control, PBS was 
administered with the same schedule. 
Intratracheal administration was performed using a Micro Sprayer® 
aerosolizer (IA-1C; Penn-Century Inc., Philadelphia, PA, USA) attached to a 
high-pressure syringe (FMJ-250; Penn-Century). Mice were anesthetized by 
intraperitoneal injection of tribromoethanol, and 50 µl of reagent was instilled 
with the sprayer. After intratracheal treatment, mice were kept in an upright 
position for one minute to allow sufficient spreading of the fluid throughout the 
lungs. 
 
Histological analyses 
The trachea was cannulated and the lungs were perfused with 
paraformaldehyde at a constant pressure of 20 cmH2O. The trachea was clamped 
and the lungs were removed and fixed overnight at 4˚C in 4% paraformaldehyde. 
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After paraffin embedding, sections (4 µm thickness) were subjected to 
hematoxylin and eosin (HE) staining. 
A standard morphometric technique was used to determine the presence of 
emphysematous changes in the lungs. To quantify mean linear intercept (MLI) 
and destructive index (DI), 10 randomly selected fields in each section were 
evaluated by microscopic observation. MLI was obtained by dividing the total 
length of a line drawn across the lung section by the total number of intercepts 
encountered. DI was measured by manual point counting and calculated with the 
formula: DI=D/(D+N) x 100 (%), where D indicates “destroyed” and N indicates 
“normal” points according to methods previously described (13). 
 
Western blot array analysis 
Mice with instillation of CSS+LPS according to Protocol B were anesthetized and 
sacrificed on day 28. Then, the trachea of each mouse was exposed and lavaged 
with 1 ml ice-cold PBS twice (2 ml total) using a 20-gauge catheter. Collected 
bronchoalveolar lavage fluid (BALF) from three mice was mixed and concentrated 
with an Amicon Ultra Centrifugal Filter Device (Millipore, Billerico, MA, USA) to 
a final volume of 2 ml. The resulting sample was subjected to RayBio® Biotin 
Label-based Mouse Antibody Array 1 (RayBiotech, Inc., Norcross, GA), and 
changes in expression levels of 308 inflammation-related proteins in the BALF 
sample were evaluated. The array was performed according to the manufacturer’s 
instructions. Using a densitometer, each signal was normalized to the positive 
internal control included in the array membrane and expressed as arbitrary units. 
 
Statistical analyses 
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Data are shown as mean ± S.E. Statistical analysis of differences between the 
two groups was performed using Student’s t-test. A probability value of P < 0.05 
was considered to indicate statistical significance. 
 
 
Results and Discussion 
 
Establishment of mouse COPD model 
It has been clearly shown that intratracheal administration of LPS and CSS 
can induce emphysema in the guinea pig in an extremely short time compared 
with animal models of cigarette smoke exposure (6, 7). We therefore applied the 
protocol of the guinea pig COPD model to mice, with adjustment of reagent 
volume and concentration according to the weight of each animal, and examined 
the histopathological changes in the lungs of mice. Protocol A followed in this 
experiment is shown in Fig. 1A. Typical histopathological findings are shown in 
Fig. 1B. The lung architecture was normal in the PBS group. However, the lung 
tissue exposed to CSS and LPS in an alternating sequential manner showed 
marked accumulation of inflammatory cells and thickening of the alveolar walls. 
On the other hand, typical pathologic changes of pulmonary emphysema were 
rarely observed, and hyperplasia of bronchial epithelial cells observed in patches 
was mild but not severe. Thus, the histological changes in the lung of mice 
committed to Protocol A were similar to those of the inflammatory phase of acute 
lung injury (ALI) (14). In preliminary experiments, we confirmed that the 
manifestation of an ALI-like profile could be dependent on the concentration or 
administration timing of LPS. Therefore, we evaluated the method with the 
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following modifications: (A) providing a recovery period after final administration; 
(B) diluting the LPS concentration; and (C) increasing the frequency of LPS 
administration. Then, we established an efficient protocol to induce COPD in mice, 
which is shown as Protocol B (Fig. 2A). In the CSS+LPS-administered group, 
alveolar wall destruction associated with alveolar space enlargement was 
observed. On the other hand, the lung of mice in the CSS+LPS group did not show 
typical bronchial epithelial cell hyperplasia and the findings were nearly 
consistent with the histological profile in the PBS group (Fig. 2B). To further 
assess the emphysematous profile in the lung in the CSS+LPS-administered 
group, MLI and DI were measured. Both MLI and DI were significantly higher in 
the CSS+LPS group than in the PBS group (Fig. 2C&D). These results 
statistically support the histopathological findings. 
LPS is a glycolipid component of gram-negative bacterial cell walls and is used 
because of its pro-inflammatory effect. In an acute model, LPS induces a mixed 
inflammatory reaction with an increase in neutrophils and upregulation of 
inflammatory cytokines (14). However, with chronic administration over several 
weeks, LPS administration produces emphysema-like changes in the mouse lung 
that are associated with apoptosis of structural cells (15). In humans, chronic 
occupational exposure to LPS contained in organic dusts, such as grain dust and 
swine dust, is known to result in airflow obstruction in agricultural workers (16, 
17). These reports suggest that, similarly to cigarette smoking, LPS is a potent 
pathogenic substance for COPD. At least in inducing emphysematous changes in 
mice, frequent administration of a relatively low dose of LPS in combination with 
CSS may be crucial. 
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BALF analysis of mouse COPD model 
To elucidate the change of microenvironment in the lung showing emphysema, 
BALF was subjected to WB array. As shown in Fig. 3A, WB array analysis showed 
a clear tendency toward an increase in various cytokine/chemokine levels in 
BALF from the CSS+LPS group compared with that from the PBS group. In 
BALF from the PBS group, no signal was detected except ICK (inhibitor of 
cyclin-dependent kinase) under our experimental condition. Among the 
CSS+LPS-induced proteins, molecules reported to be related to COPD are shown 
in Fig. 3B (18-25). 
It is generally believed that cigarette smoke-induced emphysema is caused by 
an imbalance between protease and antiprotease activity, where an excess of 
proteolytic enzymes overwhelms the local antiproteolytic defences, leading to 
matrix destruction and emphysema (2). At least under our experimental condition, 
antiproteolytic molecules like tissue inhibitor of metalloproteinases (TIMPs) 
listed in the array as target proteins were not detected in BALF. In contrast, one 
of the matrix metalloproteinases (MMPs), MMP-12, was increased in BALF from 
the CSS+LPS group (Fig. 3B). MMP-12 is mainly produced by macrophages and 
degrades extracellular matrix components, among which elastin is the major 
constituent of the alveolar wall (22). Targeted disruption of the MMP12 
(macrophage metalloelastase) gene protects mice against smoke-induced 
emphysema (23). In humans, enhanced MMP-12 activity was shown in sputum 
from patients with COPD in comparison with samples from control subjects, and 
the number of MMP-12-expressing-macrophages was higher in BAL samples from 
COPD patients than in those from control subjects (24). These findings strongly 
suggest that MMP-12 has a crucial role in the structural changes in the lungs of 
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COPD patients, and support that MMP-12 plays a pathophysiological role also in 
our mouse COPD model. 
In addition to MMP-12, molecules such as KC and IL-27 that were increased in 
BALF from the CSS+LPS group (Fig. 3B) were reported to be associated with the 
pathogenesis of COPD (19, 20). KC is a mouse homolog of human chemokine 
CXCL1 and plays an important role in the recruitment and activation of 
inflammatory cells. In humans, CXCL1 level was significantly increased in 
sputum from patients with COPD compared with non-smokers and healthy 
smokers (20). IL-27 is an early product of activated antigen-presenting cells and 
drives T-cell differentiation (26). Sputum and plasma levels of IL-27 were 
significantly elevated in COPD patients compared with healthy control subjects. 
Likewise, the concentration of IL-27 in sputum was negatively correlated with 
forced expiratory volume in 1 second (FEV1) in COPD patients, suggesting a 
possible relationship between IL-27 and disease severity (19). Taken together, 
these results indicate that CSS+LPS-induced MMP-12, KC and IL-27 may in 
concert contribute to the development of emphysema. Furthermore, IL-16, leptin 
and TCA-3 have been reported as biomarkers in an animal COPD model or in 
patients with COPD (18, 21, 25). Their upregulation in BALF from the CSS+LPS 
group supports the reliability of our mouse COPD model. 
 
Involvement of p38 in pathogenesis of COPD 
We established a mouse emphysema model. We next elucidated whether p38 
activation in alveoli could contribute to the pathogenesis of COPD. To precisely 
assess this possibility, MKK6 c.a.-transgenic (TG) mice and WT littermates were 
used to create a mouse COPD model. As shown in Fig. 4A, the resting lung 
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histological profiles (PBS groups) were consistent between MKK6 c.a.-TG mice 
and WT littermates, indicating that the SP-C-3HA-tag-MKK6 transgene itself did 
not induce histological changes in the lung parenchyma. We have confirmed by 
real-time PCR that MKK6 c.a.-TG mice have two copies of the transgene  
(Supplemental Fig. 2), whose effect is modest and may upregulate the intrinsic 
activity of p38 but not lead to sufficient p38 activation to drive an inflammatory 
response. This notion was supported by the facts that detectable probability but 
not intensity of phospho-p38-LI in type II alveolar epithelial cells increased in 
MKK6 c.a.-TG mice compared with WT littermates (Supplemental Fig. 1E). On 
the other hand, alveolar wall destruction and space enlargement induced by 
CSS+LPS were observed in both MKK6 c.a.-TG mice and WT littermates, the 
severity of which was advanced in MKK6 c.a.-TG mice compared with WT 
littermates (Fig. 4A). The hyperplasic changes in bronchial epithelial cells were 
not typical and were consistent between the two genotypes (data not shown). In 
accord with the histopathological findings, both MLI and DI were significantly 
higher in MKK6 c.a.-TG mice than in WT littermates (Fig. 4B&C). These results 
clearly suggest that p38 activation in the alveoli can cause deterioration of 
emphysema induced by CSS+LPS. 
To further examine whether some microenvironmental changes in the alveoli 
are related to the deterioration of emphysema in MKK6 c.a.-TG mice, WB array 
analysis was performed. BALF showed an increase in 72/308 and 15/308 proteins 
in MKK6 c.a.-TG mice and WT littermates, respectively, indicating that MKK6 
c.a.-TG mice show high sensitivity to CSS+LPS application compared with WT 
littermates. Molecules reported to be related to COPD and induction of its indices 
are shown in Table 1 (18-25, 27-31). An increase in COPD-related molecules such 
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as IL-16, IL-27, KC, leptin, MMP-12 and TCA-3 was observed in both MKK6 
c.a.-TG mice and WT littermates. Most of them were further upregulated in 
MKK6 c.a.-TG mice compared with WT littermates. In addition, an increase in 
expression of adiponectin, CRP (C-reactive protein), I-TAC (interferon-inducible T 
cell α chemoattractant), prolactin and uPAR (urokinase-type plasminogen 
activator receptor) was observed specifically in BALF from MKK6 c.a.-TG mice. 
Adiponectin has been reported to be involved in the pathogenesis of COPD as 
follows: adiponectin stimulates airway epithelial cells in an autocrine/paracrine 
manner to produce IL-8 in COPD patients, and plasma adiponectin level is 
increased in COPD patients (27, 28). Although the correlation between p38 
activity and expression of adiponectin has never been shown, our present data 
suggest that p38 mediates an increase in adiponectin expression. The 
p38/adiponectin/IL-8 axis is of interest in the pathogenesis of COPD. Previous 
reports have demonstrated that both human and mouse adiponectin promoter 
regions involve the cAMP-responsive element (CRE) and that the CRE functions 
as a positive regulator of the mouse adiponectin gene transcription (32, 33). 
Moreover, we have demonstrated that p38 could activate the CRE in the proximal 
promoter region of IL17 gene through phosphorylation of CREB and ATF2 (9). 
These facts tempt us to consider that the CRE may play a crucial role in the 
p38-induced adiponectin expression. In addition to adiponectin, CRP, I-TAC, 
prolactin and uPAR are recognized as biomarkers of COPD (29-31). Taken 
together, these findings indicate that alveolar epithelial cells with high intrinsic 
p38 activity may be committed to efficiently produce pathophysiological 
substances leading to emphysema in response to CSS+LPS. Notably, the 
expression level of MMP-12 in BALF from MKK6 c.a.-TG mice was nearly five 
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times higher than that in WT littermates. In chondrocytes, a possible relationship 
between p38 signaling and MMP-12 expression is suggested (34). Although a 
precise mechanism for p38-regulated MMP-12 expression in the lung is still 
unknown, p38 can contribute to the development of emphysema at least through 
MMP-12 induction. Likewise, expression of TIMPs, antiproteolytic molecules, was 
not detected in BALF from either MKK6 c.a.-TG mice or WT littermates. Thus, 
protease-antiprotease imbalance may be more enhanced in the bronchoalveolar 
space of MKK6 c.a.-TG mice with CSS+LPS instillation compared with WT 
littermates. 
The p38 signaling pathway is activated by a variety of extracellular stimuli 
including osmotic shock, inflammatory cytokines, and toll like receptor (TLR) 
agonist. Once activated, p38 phosphorylates a variety of substrates such as other 
downstream kinases and transcription factors, and plays a central role in 
inflammatory processes. p38 inhibitors efficiently reduce cytokine production 
from various types of cells including alveolar macrophages (8, 35). By virtue of the 
anti-inflammatory potency of p38 inhibitors, several p38 inhibitors are in clinical 
trials for the treatment of COPD (36, 37). However, little is known about the 
precise mechanism by which p38 mediates the pathogenesis of COPD. In the 
present study, we clearly demonstrated that p38 in type II alveolar epithelial cells 
positively contributes to the pathogenesis of emphysema. 
 
Conclusions 
We have established a mouse model of COPD that can be produced in a relatively 
short period of time. Furthermore, p38 in alveolar epithelial cells can play a 
crucial role as a driving force for emphysematous changes in our mouse COPD 
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model. This mouse model is expected to be a useful tool for elucidating the 
pathogenesis of COPD and drug development. 
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Figure Legends 
 
Figure 1: CSS and LPS-induced histopathological changes in the lung. A) Time 
schedule of CSS and LPS administration (protocol A). B) Histopathological 
findings in the lung in response to CSS-LPS. Arrows and arrowheads represent 
infiltrated macrophages and neutrophils, respectively. 
 
Figure 2: CSS+LPS-induced histopathological changes in the lung. A) Time 
schedule of CSS+LPS administration (protocol B). B) Histopathological findings in 
the lung in response to CSS+LPS. C) Mean linear intercept (MLI), as a measure of 
interalveolar wall distance, was determined by light microscopy. Data represent 
mean ± S.E. (n=7). The difference between the two groups was statistically 
significant (*P < 0.05) by Student’s t-test for unpaired values. D) Destructive 
index (DI) as a measurement of lung parenchymal destruction. Data represent 
mean ± S.E. (n=7). The difference between the two groups was statistically 
significant (*P < 0.05) by Student’s t-test for unpaired values. 
 
Figure 3: WB array analysis of BALF from mice treated with CSS+LPS. A) 
Typical profiles of protein array for 308 molecules. CSS+LPS-induced expression 
levels of cytokines/chemokines in BALF. B) CSS+LPS-upregulated molecules 
related to progression of COPD. Six molecules were selected, and their signals 
from two experiments were shown. C) Densitometric analysis of the molecules 
shown in B. Closed bars represent molecules that participate in COPD proved 
experimentally. Open bars represent molecules recognized as biomarkers for 
COPD. Induction ratio is expressed as arbitrary units relative to the positive 
internal control. 
 
Figure 4: Enhancement of emphysematous changes induced by CSS+LPS in 
MKK6 c.a.-TG mice A) Histopathological findings in the lung in response to 
CSS+LPS in MKK6 c.a.-TG mice and WT littermates. B) MLI, an index of 
enlargement of alveolar air spaces. Data represent mean ± S.E. (n=7). The 
difference between the two groups was statistically significant (*P < 0.05) by 
Student’s t-test for unpaired values. C) DI, a measurement of lung parenchymal 
destruction. Data represent mean ± S.E. (n=7). The difference between the two 
groups was statistically significant (*P < 0.05) by Student’s t-test for unpaired 
values. 
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Basic information for MKK6 c.a.-TG mice. (A) Structure of transgene for generating TG mice. (B) 
Determination of the transgene-derived protein in the lung. Lung homogenates from WT and TG mice 
were subjected to WB analysis with anti-HA-tag antibody (Roche). (C) Localization of the 
transgene-derived protein in the alveoli. The lung sections (4 µm thickness) from TG mice were stained 
with anti-proSP-C antibody (Millipore) and anti-HA-tag antibody followed by reaction with Alexa Fluor488- 
and Alexa Fluor594-conjugated second antibodies. Arrowheads represent SP-C+/HA+ cells. (D) Genotyping 
by PCR analysis of tail-derived DNA. Using the three primers for one cycle at 98°C for 2 min followed by 35 
cycles at 98°C for 15 s, 52°C for 45 s, 68°C for 1 min, with an extension step of 7 min at 68°C at the end of 
the last cycle, PCR products were determined. (E) Phospho-p38-like immunoreactivity (LI) in the resting 
lung from WT littermates was sparsely observed with a weak signal. Arrowheads represent P-p38+ type II 
alveolar epithelial cells. In the resting lung from TG mice, phospho-p38-LI was weak, but the detectable 
probability increased. 
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Determination of transgene copy number of TG mice by quantitative real-time PCR (Q-PCR). For the 
transgene amplification, the following primers were used : 5'-TTTGTTGACTTTACCTCACAG-3' and 
5'-AAATGTGGTATGGCTGATTATG-3'. In combination with QuantiFast SYBR Green PCR Kit (Qiagen), the 
Q-PCR was run in PikoReal 96-well system (Thermo scientific) using the following amplification 
parameters: 95°C for 7 min followed by 40 cycles at 95°C for 5 s, 55°C for 10 s, 72°C for 30s. Data were 
collected and analyzed with PikoReal Software 2.1. (A) Standard curve for the transgene. Control DNA 
samples in serially diluted (10-fold) pSPC-3HA-tag-hMKK6 c.a. vector were subjected to Q-PCR. All samples 
were run in triplicate. (B) Calculated copy number of the transgene in TG mice. Ct, cycle threshold. 
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